Amgen reports positive top-line results from XGEVA (Denosumab) Phase 3 trial for delay of bone complications in multiple myeloma patients

Amgen has announced that a Phase 3 study evaluating XGEVA (denosumab) versus zoledronic acid met the primary endpoint of non-inferiority in delaying the time to first on-study skeletal-related event (SRE) in patients suffering with multiple myeloma.

Source: Drug Development Technology - October 23, 2016 Category: Pharmaceuticals Source Type: news